|
|
|
Volumn 4, Issue 3, 2005, Pages 186-190
|
|
Farnesyltransferase inhibitors in myelodysplastic syndrome.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ENZYME INHIBITOR;
FARNESYL TRANS TRANSFERASE;
HRAS PROTEIN, HUMAN;
LONAFARNIB;
PIPERIDINE DERIVATIVE;
PROTEIN P21;
PYRIDINE DERIVATIVE;
QUINOLONE DERIVATIVE;
TIPIFARNIB;
TRANSFERASE;
ACUTE DISEASE;
AGED;
BLOOD DISEASE;
CHEMISTRY;
DISEASE COURSE;
DRUG ANTAGONISM;
DRUG EFFECT;
ENZYMOLOGY;
GENETICS;
HUMAN;
METABOLISM;
MIDDLE AGED;
MYELODYSPLASTIC SYNDROME;
MYELOID LEUKEMIA;
ONCOGENE RAS;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHYSIOLOGY;
PROTEIN PROCESSING;
REMISSION;
REVIEW;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
ACUTE DISEASE;
AGED;
ALKYL AND ARYL TRANSFERASES;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
DISEASE PROGRESSION;
ENZYME INHIBITORS;
FARNESYLTRANSTRANSFERASE;
GENES, RAS;
HEMATOLOGIC NEOPLASMS;
HUMANS;
LEUKEMIA, MYELOID;
MIDDLE AGED;
MYELODYSPLASTIC SYNDROMES;
PIPERIDINES;
PROTEIN ISOPRENYLATION;
PROTEIN PROCESSING, POST-TRANSLATIONAL;
PROTO-ONCOGENE PROTEINS P21(RAS);
PYRIDINES;
QUINOLONES;
REMISSION INDUCTION;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
|
|
EID: 23844505374
PISSN: None
EISSN: 15410714
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (19)
|
|
References (37)
|
